We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 426

Other industry news
  • Borden Ladner Gervais LLP
  • Canada
  • January 9 2013

Health Canada has announced a Consultation on the new Prescription Drug List. The consultation is open for comment until March 7, 2013. Health Canada has


Intellectual property weekly abstracts bulletin
  • Borden Ladner Gervais LLP
  • Canada
  • June 10 2013

In November, the Supreme Court issued its decision in the sildenafil case, and, as part of its order, found the patent to be invalid. As this case was


Decisions in leave to appeal to the Supreme Court
  • Borden Ladner Gervais LLP
  • Canada
  • March 18 2013

The Supreme Court is releasing their judgment for two leave decisions this Thursday. The first, Gilead Science Canada Inc. v. Minister of Health


Other patent and trademark news
  • Borden Ladner Gervais LLP
  • Canada
  • December 24 2013

Parliament has published amendments to the Patent Rules regarding becoming a patent agent and the Trademark Regulations regarding becoming a


Fact-specific issues relevant to calculating section 8 damages are decided
  • Borden Ladner Gervais LLP
  • Canada
  • December 18 2013

This decision provides answers to certain issues that would allow the parties to calculate the loss under section 8 of thePM(NOC) Regulations that


Oder of prohibition issues no promise to treatment in humans or reduced side effects was found
  • Borden Ladner Gervais LLP
  • Canada
  • April 30 2014

Pfizer’s Canadian Patent No. 2,177,576 for Celebrex has withstood Apotex’s allegations and was found to be valid; therefore the Minister is


Appeal relating to double patenting and sufficiency of tadalafil patent dismissed
  • Borden Ladner Gervais LLP
  • Canada
  • November 9 2016

The Federal Court of Appeal considered an appeal from Apotex relating to double patenting and insufficiency of a patent claiming the use of tadalafil


The Court grants an innovator standing and the right to be made a party in a judicial Review of the Minister’s Decision relating to the application of the data protection regime
  • Borden Ladner Gervais LLP
  • Canada
  • April 26 2014

This was a motion that raised the issue of an innovator’s standing and right to be made a party to a judicial review of the Minister of Health’s


Other industry news
  • Borden Ladner Gervais LLP
  • Canada
  • January 16 2012

A revised NPDUIS Analytical Study Wholesale Up-charge Policies of Canada’s Public Drug Plans has been published on the Patented Medicine Prices Review Board website


Intellectual property weekly abstracts bulletin
  • Borden Ladner Gervais LLP
  • Canada
  • July 15 2013

Obviousness and lack of patentable subject matter were cited by the Examiner as the basis for rejecting the patent application before the Patent